title: Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report.
abstract: A 67-year-old male patient who was diagnosed with primary myelofibrosis 4 years ago did not respond to conventional therapies. The splenomegaly progressively increased, which caused spleen infarctions and led to the decision to perform a splenectomy procedure. After splenectomy, the patient started treatment with ruxolitinib. In the first month of ruxolitinib treatment, the patient became transfusion-free and all constitutional symptoms disappeared. However, in the sixth month of ruxolitinib treatment, the disease transformed to acute myeloblastic leukemia, and the patient died 1 month later. This is the first case report that shows the effects of ruxolitinib in a splenectomized patient.
authors: Meltem
authors: M
authors: Aylı
authors: Muhit
authors: M
authors: Özcan
authors: Ufuk University Faculty of Medicine, Department of Hematology, Ankara, Turkey E-mail: guldanecengiz@gmail.com.
authors: Güldane
authors: G
authors: Cengiz Seval
mesh_terms: D000368:Aged; D001228:Aspergillosis / Q000209:etiology; D001803:Blood Transfusion; D003613:Danazol / Q000627:therapeutic use; D018450:Disease Progression; D004351:Drug Resistance; D017809:Fatal Outcome; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects / Q000627:therapeutic use; D053614:Janus Kinase 2 / Q000037:antagonists & inhibitors; D000077269:Lenalidomide; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D008297:Male; D009570:Nitriles; D055728:Primary Myelofibrosis / Q000150:complications / Q000188:drug therapy* / Q000201:enzymology / Q000601:surgery; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011720:Pyrazoles / Q000627:therapeutic use*; D011743:Pyrimidines; D013156:Splenectomy; D013159:Splenic Infarction / Q000209:etiology / Q000601:surgery; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D009570:Nitriles; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011743:Pyrimidines; D013792:Thalidomide; C540383:ruxolitinib; C507924:JAK2 protein, human; D053614:Janus Kinase 2; D000077269:Lenalidomide; D003613:Danazol; D006918:Hydroxyurea